Left ventricular assist device-induced coagulation and platelet activation and effect of the current anticoagulant therapy regimen

Clinical and Applied Thrombosis/Hemostasis

Volumn 19, Issue 3, 2013, Pages 249-255

  Ashbrook, Michael ^a   Walenga, Jeanine M ^a   Schwartz, Jeffrey ^a   Heroux, Alain ^a   Jeske, Walter P ^a   Escalante, Vicki ^a   Bakhos, Mamdouh ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

coagulation; heart failure; platelets; ventricular assist device

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; VON WILLEBRAND FACTOR; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LEFT VENTRICULAR ASSIST DEVICE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOELASTOGRAPHY;

COAGULATION; HEART FAILURE; PLATELETS; VENTRICULAR ASSIST DEVICE;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION; FEMALE; FLOW CYTOMETRY; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PROSPECTIVE STUDIES; THROMBELASTOGRAPHY;

EID: 84878880948     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029612464900     Document Type: Article

References (20)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011 ; 123 (4). e18 - e209
2. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: twenty-seventh official adult heart transplant report-2010. J Heart Lung Transplant. 2010 ; 29 (10). 1089-1103
3. Slaughter MS, Rogers JG, Milano CA, et al. Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med. 2009 ; 361 (23). 2241-2251
4. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2011 ; 345 (20). 1435-1443
5. Schaffer JM, Arnaoutakis GJ, Allen JG, et al. Bleeding complications and blood product utilization with left ventricular assist device implantation. Ann Thorac Surg. 2011 ; 91 (3). 740-747
6. John R, Kamdar F, Liao K, et al. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device. J Thorac Cardiovasc Surg. 2008 ; 136 (5). 1318-1323
7. Heilmann C, Geisen U, Beyersdorf F, et al. Acquired von willebrand syndrome in patients with ventricular assist device or total artificial heart. Thromb Haemost. 2010 ; 103 (5). 962-967
8. Steinlechner B, Dworschak M, Birkenberg B, et al. Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg. 2009 ; 87 (1). 131-137
9. http://facs.scripps.edu/software.html. Accessed March 9, 2012.
10. Walenga JM, Hoppensteadt D, Fareed J, Pifarré R. Hemostatic abnormalities in total artificial heart patients as detected by specific blood markers. Ann Thorac Surg. 1992 ; 53 (5). 844-850
11. Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. Blood. 2010 ; 116 (5). 693-701
12. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with non-valvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999 ; 131 (12). 927-934
13. Savage B, Ruggeri ZM Platelets. 1 st ed. San Diego, CA: Elsevier Science; 2002; 217. Michelson AD, ed. San Diego, CA: Elsevier Science ; 2002: 217.
14. Moake JL, Turner NA, Stathopoulos NA, Nolasco L, Hellums JD. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF mulitmers, requires adenosine diphosphate, and is resistant to aspirin. Blood. 1988 ; 71 (5). 1366-1374
15. Haberichter SL, Balistreri M, Christopherson P, et al. Assay of the von willebrand factor (VWF) propeptide to identify patients with type 1 von willebrand disease with decreased VWF survival. Blood. 2006 ; 108 (10). 3344-3351
16. Vincentelli A, Susen S, Le Tourneau T, et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med. 2011 ; 349 (4). 343-349
17. Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von willebrand factor-cleaving protease. Best Pract Res Clin Haematol. 2001 ; 14 (2). 437-454
18. Sugimoto M, Matsui H, Mizuno T, et al. Mural thrombus generation in type 2A and 2B von willebrand disease under flow conditions. Blood. 2003 ; 101 (3). 915-920
19. Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). J Am Coll Cardiol. 2009 ; 53 (23). 2162-2167
20. Freyssinet J. Cellular microparticles: what are they bad or good for?. J Thromb Haemost. 2003 ; 1 (7). 1655-1662